胶质母细胞瘤相关药物治疗的研究进展

Research progress on drug therapy for glioblastoma

胶质母细胞瘤(GBM)是一种起源于颅内神经胶质细胞的高级别恶性肿瘤,复发率高,预后差。标准治疗模式是手术切除肿瘤联合放化疗,但因血脑屏障的限制和对化疗药物的耐药机制使疗效大大降低。近年来,针对替莫唑胺、亚硝基类、贝伐珠单抗等抗GBM常用药物作用及耐药机制的不断研究,发现了多种有效的联合治疗方式。此外,在纳米技术领域内,探索新方法对GBM化疗进程产生了极大的影响。本文综述了GBM常用药物的耐药机制、有效联合治疗及其他提高药物治疗疗效策略的最新研究进展。

Glioblastoma(GBM) is a high-grade malignant tumor originating from intracranial glia,with a high recurrence rate and poor prognosis.The standard treatment mode is surgical resection of tumor combined with radiotherapy and chemotherapy,but the effect is greatly reduced due to the limitation of Blood-brain barrier and the mechanism of drug resistance to chemotherapy drugs.In recent years,according to the continuous research on the effect and drug resistance mechanism of the existing Temozolomide,Nitroso,Bevacizumab and other commonly used anti GBM drugs,a variety of effective combination therapies have been found.In addition,exploring new methods in the field of nanotechnology has had a significant impact on the process of GBM.This article reviews the latest research progress on the resistance mechanisms,effective combination therapy,and other strategies to improve efficacy of commonly used anti GBM chemotherapy drugs.